Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more
Articolo
Data di Pubblicazione:
2019
Abstract:
Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk-benefit of betrixaban in patients aged ≥ 80 years enrolled in the APEX trial.
Tipologia CRIS:
Articolo su Rivista
Keywords:
betrixaban; elderly; medical patients; prophylaxis; venous thromboembolism; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Blood Coagulation; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Progression-Free Survival; Pyridines; Risk Assessment; Risk Factors; Time Factors; Venous Thromboembolism
Elenco autori:
Ageno, Walter; Lopes, Renato D; Yee, Megan K; Hernandez, Adrian; Hull, Russell D; Goldhaber, Samuel Z; Gibson, C Michael; Cohen, Alexander T
Link alla scheda completa:
Pubblicato in: